Compare iShares MSCI Taiwan ETF (EWT) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Humana Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.04 (market cap $12.74B), while Humana Inc trades at $429.8 (market cap $46.49B). The key difference: Humana Inc is far larger — about 3.6× iShares MSCI Taiwan ETF's market cap, and Humana Inc pays a 0.91% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Humana Inc for 53 Days on average.
| EWT | HUM | |
|---|---|---|
Market Cap | $12.74B | $46.49B |
Volume | 8,470,920 | 2,567,704 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $409.85 |
52-Week Low | $60.03 | $163.67 |
Typical Hold Time | 52 Days | 53 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.01, down 1.92% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of its portfolio. Recent news highlights Taiwan's strategic importance in AI chip manufacturing and ongoing US-Taiwan economic cooperation, with Taiwanese companies planning $20 billion in US investments driven by AI demand (Reuters, 2026-09-02).
The outlook remains positive given Taiwan's central role in AI semiconductor supply chains, though geopolitical tensions with China present significant risks. Analyst sentiment is generally bullish with institutional investors increasing positions, including Bank of America's 22.4% stake increase in Q2 2026. Key support levels at $110-$112 provide downside protection while resistance sits at $115-$117.
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
